Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

AOD-9604 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established AOD-9604 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. The review describes the pivotal oral obesity study as running 24 weeks, and characterises the human evidence base overall as short-term 10.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • AOD-9604 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established AOD-9604 cycle length?
No. Human studies administered AOD-9604 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of AOD-9604?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
AOD-9604 dosing reference Full research page

References

  1. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Endocrinology. 2001
  2. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Horm Res. 2000
  3. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model Ann Clin Lab Sci. 2015
  4. Detection and in vitro metabolism of AOD9604 Drug Test Anal. 2015
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page modified April 2026) FDA. 2026
  6. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  7. PubChem compound record for AOD-9604 (CID 71300630) PubChem. 2026
  8. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med. 2026
  9. Drugs@FDA application data queried through openFDA for AOD-9604 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026